Proteasome proteolysis supports stimulated platelet function and thrombosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 1, 2014, Pages 160-168

  Gupta, Nilaksh ^a,b   Li, Wei ^a   Willard, Belinda ^a   Silverstein, Roy L ^a   McIntyre, Thomas M ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND STATE UNIVERSITY   (United States)

Author keywords

Cell derived microparticles; Cytoskeletal proteins; Proteasome endopeptidase complex; Thrombin

Indexed keywords

ACTIN BINDING PROTEIN; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CYTOPLASM PROTEIN; CYTOSKELETON PROTEIN; FILAMIN A; GLYCOPROTEIN IB; GLYCOPROTEIN IB ALPHA; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN P53; PROTEINASE; RISTOCETIN; THROMBIN; UBIQUITIN; UBIQUITINATED PROTEIN; VON WILLEBRAND FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY REACTION; ARTICLE; BLOOD CLOT RETRACTION; CARBOXY TERMINAL SEQUENCE; CAROTID ARTERY; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; CYTOSKELETON; EX VIVO STUDY; EXTERNAL CAROTID ARTERY; FERRIC CHLORIDE-INDUCED THROMBOSIS; MASS SPECTROMETRY; MEMBRANE MICROPARTICLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN MODIFICATION; TANDEM MASS SPECTROMETRY; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGLUTINATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOSIS; UBIQUITINATION;

EID: 84891826294     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.302116     Document Type: Article

References (51)

1. Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, Pazdur R. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res. 2007;13(18 Pt 1):5291-5294
2. Adams J. The proteasome: A suitable antineoplastic target. Nat Rev Cancer. 2004;4:349-360
3. Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist. 2003;8:508-513
4. Lonial S, Waller EK, Richardson PG, et al SUMMIT/CREST Investigators. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005;106:3777-3784
5. Nayak MK, Kulkarni PP, Dash D. Regulatory role of proteasome in determination of platelet life span. J Biol Chem. 2013;288:6826-6834
6. Shen Y, Zhou X, Wang Z, Yang G, Jiang Y, Sun C, Wang J, Tong Y, Guo H. Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma. Leuk Res. 2011;35:147-151
7. Zangari M, Guerrero J, Cavallo F, Prasad HK, Esseltine D, Fink L. Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma. Haematologica. 2008;93:953-954
8. Goto S, Ikeda Y, Saldívar E, Ruggeri ZM. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J Clin Invest. 1998;101:479-486
9. Kroll MH, Harris TS, Moake JL, Handin RI, Schafer AI. von Willebrand factor binding to platelet GpIb initiates signals for platelet activation. J Clin Invest. 1991;88:1568-1573
10. Ithychanda SS, Hsu D, Li H, Yan L, Liu DD, Liu D, Das M, Plow EF, Qin J. Identification and characterization of multiple similar ligand-binding repeats in filamin: Implication on filamin-mediated receptor clustering and cross-Talk. J Biol Chem. 2009;284:35113-35121
11. Cranmer SL, Ashworth KJ, Yao Y, Berndt MC, Ruggeri ZM, Andrews RK, Jackson SP. High shear-dependent loss of membrane integrity and defective platelet adhesion following disruption of the GPIbalpha-filamin interaction. Blood. 2011;117:2718-2727
12. Greco NJ, Tandon NN, Jones GD, Kornhauser R, Jackson B, Yamamoto N, Tanoue K, Jamieson GA. Contributions of glycoprotein Ib and the seven transmembrane domain receptor to increases in platelet cytoplasmic [Ca2+] induced by alpha-Thrombin. Biochemistry. 1996;35:906-914
13. Bergmeier W, Piffath CL, Goerge T, Cifuni SM, Ruggeri ZM, Ware J, Wagner DD. The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc Natl Acad Sci U S A. 2006;103:16900-16905
14. Li W, McIntyre TM, Silverstein RL. Ferric chloride-induced murine carotid arterial injury: A model of redoxpathology. Redox Biol. 2013;1:50-55
15. Li W, Febbraio M, Reddy SP, Yu DY, Yamamoto M, Silverstein RL. CD36 participates in a signaling pathway that regulates ROS formation in murine VSMCs. J Clin Invest. 2010;120:3996-4006
16. Nussbaum AK, Dick TP, Keilholz W, Schirle M, Stevanović S, Dietz K, Heinemeyer W, Groll M, Wolf DH, Huber R, Rammensee HG, Schild H. Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. Proc Natl Acad Sci U S A. 1998;95:12504-12509
17. Dick TP, Nussbaum AK, Deeg M, Heinemeyer W, Groll M, Schirle M, Keilholz W, Stevanović S, Wolf DH, Huber R, Rammensee HG, Schild H. Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants. J Biol Chem. 1998;273:25637-25646
18. Arendt CS, Hochstrasser M. Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation. Proc Natl Acad Sci U S A. 1997;94:7156-7161
19. Chen P, Hochstrasser M. Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly. Cell. 1996;86:961-972
20. Dahlmann B, Ruppert T, Kuehn L, Merforth S, Kloetzel PM. Different proteasome subtypes in a single tissue exhibit different enzymatic properties. J Mol Biol. 2000;303:643-653
21. Dahlmann B, Ruppert T, Kloetzel PM, Kuehn L. Subtypes of 20S proteasomes from skeletal muscle. Biochimie. 2001;83:295-299
22. Xu P, Duong DM, Seyfried NT, Cheng D, Xie Y, Robert J, Rush J, Hochstrasser M, Finley D, Peng J. Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation. Cell. 2009;137:133-145
23. Jacobson AD, Zhang NY, Xu P, Han KJ, Noone S, Peng J, Liu CW. The lysine 48 and lysine 63 ubiquitin conjugates are processed differently by the 26 s proteasome. J Biol Chem. 2009;284:35485-35494
24. Nalepa G, Rolfe M, Harper JW. Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov. 2006;5:596-613
25. Ault KA, Rinder HM, Mitchell J, Carmody MB, Vary CP, Hillman RS. The significance of platelets with increased RNA content (reticulated platelets). A measure of the rate of thrombopoiesis. Am J Clin Pathol. 1992;98:637-646
26. Yukawa M, Sakon M, Kambayashi J, Shiba E, Kawasaki T, Uemura Y, Murata K, Tanaka T, Nakayama T, Shibata H. Purification and characterization of endogenous protein activator of human platelet proteasome. J Biochem. 1993;114:317-323
27. Avcu F, Ural AU, Cetin T, Nevruz O. Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro. Thromb Res. 2008;121:567-571
28. Ostrowska H, Ostrowska JK, Worowski K, Radziwon P. Human platelet 20S proteasome: Inhibition of its chymotrypsin-like activity and identification of the proteasome activator PA28. A preliminary report. Platelets. 2003;14:151-157
29. Ostrowska H, Wojcik C, Omura S, Worowski K. Lactacystin, a specific inhibitor of the proteasome, inhibits human platelet lysosomal cathepsin A-like enzyme. Biochem Biophys Res Commun. 1997;234:729-732
30. Nayak MK, Kumar K, Dash D. Regulation of proteasome activity in activated human platelets. Cell Calcium. 2011;49:226-232
31. Shashkin PN, Brown GT, Ghosh A, Marathe GK, McIntyre TM. Lipopolysaccharide is a direct agonist for platelet RNA splicing. J Immunol. 2008;181:3495-3502
32. Cunningham JG, Meyer SC, Fox JE. The cytoplasmic domain of the alphasubunit of glycoprotein (GP) Ib mediates attachment of the entire GP Ib-IX complex to the cytoskeleton and regulates von Willebrand factor-induced changes in cell morphology. J Biol Chem. 1996;271:11581-11587
33. Gorlin JB, Yamin R, Egan S, Stewart M, Stossel TP, Kwiatkowski DJ, Hartwig JH. Human endothelial actin-binding protein (ABP-280, nonmuscle filamin): A molecular leaf spring. J Cell Biol. 1990;111:1089-1105
34. Morel O, Jesel L, Freyssinet JM, Toti F. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol. 2011;31:15-26
35. Cheresh DA, Leng J, Klemke RL. Regulation of cell contraction and membrane ruffling by distinct signals in migratory cells. J Cell Biol. 1999;146:1107-1116
36. Grinnell F. Signal transduction pathways activated during fibroblast contraction of collagen matrices. Curr Top Pathol. 1999;93:61-73
37. Coughlin SR, Camerer E. PARticipation in inflammation. J Clin Invest. 2003;111:25-27
38. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A. 1999;96:10403-10408
39. Michelson AD, Ellis PA, Barnard MR, Matic GB, Viles AF, Kestin AS. Downregulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, adenosine diphosphate, or an in vivo wound. Blood. 1991;77:770-779
40. Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, Kattke-Marchant K, Hussein MA. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer. 2004;101:558-566
41. Zangari M, Elice F, Fink L, Tricot G. Thrombosis in multiple myeloma. Expert Rev Anticancer Ther. 2007;7:307-315
42. Kristinsson SY, Fears TR, Gridley G, Turesson I, Mellqvist UH, Björkholm M, Landgren O. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 2008;112:3582-3586
43. Libourel EJ, Sonneveld P, van der Holt B, de Maat MP, Leebeek FW. High incidence of arterial thrombosis in young patients treated for multiple myeloma: Results of a prospective cohort study. Blood. 2010; 116:22-26
44. Ostrowska JK, Wojtukiewicz MZ, Chabielska E, Buczko W, Ostrowska H. Proteasome inhibitor prevents experimental arterial thrombosis in renovascular hypertensive rats. Thromb Haemost. 2004;92:171-177
45. Dangelmaier CA, Quinter PG, Jin J, Tsygankov AY, Kunapuli SP, Daniel JL. Rapid ubiquitination of Syk following GPVI activation in platelets. Blood. 2005;105:3918-3924
46. Daniel JL, Dangelmaier CA, Mada S, Buitrago L, Jin J, Langdon WY, Tsygankov AY, Kunapuli SP, Sanjay A. Cbl-b is a novel physiologic regulator of glycoprotein VI-dependent platelet activation. J Biol Chem. 2010;285:17282-17291
47. Kisselev AF, Callard A, Goldberg AL. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem. 2006;281:8582-8590
48. Rape M, Jentsch S. Taking a bite: Proteasomal protein processing. Nat Cell Biol. 2002;4:E113-E116
49. Fox JE, Austin CD, Reynolds CC, Steffen PK. Evidence that agonistinduced activation of calpain causes the shedding of procoagulant-containing microvesicles from the membrane of aggregating platelets. J Biol Chem. 1991;266:13289-13295
50. Bassé F, Gaffet P, Bienvenüe A. Correlation between inhibition of cytoskeleton proteolysis and anti-vesiculation effect of calpeptin during A23187-induced activation of human platelets: Are vesicles shed by filopod fragmentatioñ Biochim Biophys Acta. 1994;1190:217-224
51. Shcherbina A, Remold-O'Donnell E. Role of caspase in a subset of human platelet activation responses. Blood. 1999;93:4222-4231